Status:
UNKNOWN
Study of Serum and Urinary Biomarkers and Radiation Cystitis in Patients Treated With Radiotherapy for Localized Prostate Cancer
Lead Sponsor:
Direction Centrale du Service de Santé des Armées
Conditions:
Radiation Cystitis
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
Prostate cancer represents the 1st diagnosed cancer in men, with 50400 new cases and 8100 deaths in 2018. Improved diagnostic and therapeutic strategies have led to a 3.7% decrease in mortality betwee...
Eligibility Criteria
Inclusion
- Histologically confirmed adenocarcinoma of the prostate;
- Localized adenocarcinoma of the prostate according to the D'Amico Risk Classification for Prostate Cancer;
- Eligible for external beam radiation therapy and/or brachytherapy;
- Patient able, in the opinion of the physician-investigator, to communicate well, understand and comply with the requirements of the study;
- Patient with a phone or a computer.
Exclusion
- Patient with advanced or metastatic prostate cancer;
- Patient receiving pre-irradiation hormone therapy;
- Patient with bladder or urethral cancer or a history of it;
- Previous urinary tract surgery (bladder augmentation, cystectomy);
- Patient participating in an interventional clinical study;
- Patient with a history of pelvic irradiation;
Key Trial Info
Start Date :
March 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05246774
Start Date
March 1 2022
End Date
September 1 2024
Last Update
April 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital d'Instruction des Armées Bégin
Saint-Mandé, France, 94160